| Similar Articles |
|---|
 |
The Motley Fool
July 25, 2006
Stephen D. Simpson |
An Eye-Opening Quarter at Alcon Good news may have been overdue from the eye-care company, but the jubilation seems overdone. Investors, take note.   |
The Motley Fool
February 9, 2006
Stephen D. Simpson |
Alcon Makes Traders Cry Disappointing guidance lets some of the air out of the valuation, but not enough. |
The Motley Fool
May 1, 2006
Stephen D. Simpson |
Alcon Still Not Living Up to Valuation Though this is a very solid medical technology company, its valuation still looks too high. |
The Motley Fool
August 7, 2006
Stephen D. Simpson |
Advanced Medical Optics Still a Little Bloodshot This eye-care stock has done relatively well despite some ongoing sales issues. |
The Motley Fool
April 19, 2005
Stephen D. Simpson |
Do The Eyes Have It for Bausch & Lomb? New product launches and extensions coupled with improving margins should boost results. Investors, take note. |
The Motley Fool
February 11, 2005
Stephen D. Simpson |
For Alcon, the Eye Is the Prize Well-balanced growth continues to be the key to this ophthalmology giant. |
The Motley Fool
April 22, 2004
Brian Gorman |
Bausch & Lomb Delivers The 150-year-old eye-care company's sales aren't sizzling, but its profitability is improving. |
The Motley Fool
January 4, 2010
Brian Orelli |
You Don't Need Your Contacts In to See This Deal Novartis acts first to grab the rest of Nestle's stake in Alcon. |
The Motley Fool
April 8, 2008
Brian Lawler |
Novartis Sees More Growth Ahead Novartis makes one of the largest acquisitions in health-care history. |
The Motley Fool
November 2, 2005
Stephen D. Simpson |
AMO Focuses on the Giants Advanced Medical Optics sets its sights on the big players in eye care. Will David be able to take on the Goliaths? Investors, take note. |
The Motley Fool
March 3, 2009
Brian Orelli |
Pfizer Eyes Generic Growth Two partnerships in one day? Oh my! |
BusinessWeek
January 7, 2010
Capell & Doherty |
What Novartis Sees in Eye Care Novartis CEO Dan Vasella's $50 billion bet on Alcon could help insulate it from the vagaries of the drug business. |
The Motley Fool
July 21, 2006
Stephen D. Simpson |
Lilly Wilts Neither the valuation nor the pipeline of this pharma makes for a compelling investment case. |
The Motley Fool
October 27, 2005
Brian Gorman |
Bausch & Lomb's Cloudy Quarter An accounting scandal at a Brazilian subsidiary clouded third-quarter results, but the underlying business still looks good. Investors, take note. |
The Motley Fool
September 3, 2009
Brian Orelli |
Now That's How to Grow a Company! Dear Pfizer and Merck, you really should take note of how Abbott Labs is growing. |
The Motley Fool
April 6, 2011
Brian Orelli |
Merck Inspired to Eye Growth A bolt-on acquisition of eye-care specialist Inspire. |
The Motley Fool
May 2, 2007
Mike Havrilla |
An Eye-Opening Potential Acquisition The Biotech firm Inspire should consider buying drug-development partner InSite Vision. |
BusinessWeek
May 7, 2007
Gene G. Marcial |
A Closer Look At Cooper Turnaround efforts and a search for a new chief at Cooper, whose coopervision arm makes contact lenses, have wall street in a wait-and-see stance. |
The Motley Fool
January 20, 2010
Brian Orelli |
Those Are Fighting Words Alcon's minority shareholders fight back. |
The Motley Fool
April 22, 2008
Brian Lawler |
No Earnings Holes for Novartis The drugmaker holds its own in Q1; all three of its major divisions experienced sales growth, even in the face of some tough comparisons to last year. |
The Motley Fool
June 7, 2006
Stephen D. Simpson |
Cooper's Bleary Performance Missteps in strategy and operations for the contact lens company are coming home to roost. As is almost always the case with turnarounds, this is an idea with above-average risk, so don't make the mistake of underestimating the odds that things could get even worse. |
The Motley Fool
January 27, 2010
Brian Orelli |
Nice, Novartis, Very Nice CEO Daniel Vasella leaves on a high note. |
The Motley Fool
June 28, 2010
Brian Orelli |
The Trouble Is They're Facing a Bazooka Alcon's minority shareholders are still fighting against Novartis' takeover. |
The Motley Fool
October 21, 2008
Brian Orelli |
Novartis Is Taking the Road Less Traveled Diversification should pay off for this pharma giant. |
The Motley Fool
April 11, 2006
Rick Aristotle Munarriz |
Bausch & Lomb Sees Eye to Ay The contact lens specialist gets tripped up over its potentially infected ReNu brand. Bausch & Lomb's stock took a 9% hit in after-hours trading on the news. |
The Motley Fool
January 29, 2009
Brian Orelli |
Novartis: Diversification Isn't Good Enough Novartis has become a better diversified company, with acquisitions of vaccines specialist Chiron and 25% of eye-care specialist Alcon, but it's far from a cure all, as the fourth quarter showed. |
The Motley Fool
February 21, 2006
Stephen D. Simpson |
A Little Sand in the EYE Advanced Medical Optics' transition effort looks messy, but should pay off later this year. Investors need to monitor a few key issues here, though. |
The Motley Fool
August 10, 2010
Seth Jayson |
Marginal Performance at Alcon The more Alcon keeps of each buck it earns in revenue, the more money it has to invest in growth, fund new strategic plans, or (gasp!) distribute to shareholders. |
The Motley Fool
May 31, 2007
Billy Fisher |
Not Seeing 20/20 at Advanced Medical Optics The company recalls a contact lens solution that might be linked to a rare infection. Investors, take note. |
The Motley Fool
July 5, 2005
Brian Gorman |
Bausch & Lomb Eyes China The firm's latest purchase will add geographic diversity to its pharmaceutical business. Investors, take note. |
The Motley Fool
June 6, 2008
Brian Lawler |
Nothing Can Stop Novartis! Swiss pharmaceutical giant Novartis has bucketloads of cash, and apparently, it isn't afraid to use them. |
The Motley Fool
August 24, 2010
David Meier |
Could Alcon Be a Multibagger? Strong returns on equity can generate powerful shareholder returns. |
The Motley Fool
August 5, 2010
Seth Jayson |
Show Me the Money, Alcon With questionable cash sources comprising 4% of the cash flow from operations for Alcon, I am pretty confident things are OK. |
The Motley Fool
August 18, 2010
David Meier |
Alcon: Deflation Fighter Alcon could be a good candidate to keep you ahead of the game. |
The Motley Fool
August 10, 2010
David Meier |
Would Jeremy Grantham Buy Alcon? The seasoned pro thinks high-quality companies are on sale. Let's find the bargains. |
The Motley Fool
July 22, 2004
Nathan Slaughter |
VISX Eyes Future The vision-correction firm posts triple-digit earnings growth, capturing the attention of investors. |
The Motley Fool
July 29, 2008
Dan Dzombak |
3 Stocks Hitting High Notes These stocks are bucking the trend by hitting new highs. Take a look at: Varian Medical Systems... Alcon... Amgen... |
The Motley Fool
October 23, 2009
Brian Orelli |
Swine Flu Doesn't Need to Save Novartis The company is looking healthy all on its own. |
